RxDoctor Payments Data

Emily Kitchin, MD

Rheumatology · Indianapolis, INNPI 1366885998

Payments from drug & device makers

$957in general payments, 2019–2025

Across 41 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$384
  • AbbVie$233
  • GSK$137
  • Sobi, Inc$92
  • Johnson & Johnson$44
  • Novartis$29
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$94298%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)15$384
AbbVie15$233
GSK3$137
Sobi, Inc2$92
Johnson & Johnson2$44
Novartis2$29
Regeneron Healthcare Solutions, Inc.1$26
Lilly USA, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$957 in reported general payments places this provider in the 30th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Medicare billing

Part B allowed, 2024
$57,211
Medicare patients
209
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab126$1,122,505
Enbrel SureclickEtanercept88$698,477
RinvoqUpadacitinib48$306,775
Actemra ActpenTocilizumab49$187,234
Cosentyx Sensoready (2 Pens)Secukinumab25$179,686
Orencia ClickjectAbatacept26$146,992
Xeljanz XrTofacitinib Citrate17$104,089
BenlystaBelimumab14$65,908
Hydroxychloroquine Sulfate306$12,253
MethotrexateMethotrexate Sodium305$10,107
Leflunomide73$6,585
Mycophenolate Mofetil26$5,599
Pilocarpine Hcl29$4,338
Duloxetine Hcl42$2,910
Azathioprine25$2,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$233$306,77548 claims
GSKBenlysta$137$65,90814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →